Beta thalassemia is a blood disorder that affects the production of hemoglobin. Hemoglobin is the iron-rich protein in your ...

It’s been almost a year since the Food and Drug Administration approved the first genetic treatments for sickle cell disease.

CONVINCING evidence has been presented that the term thalassemia does not describe a specific or homogeneous entity. Bather, it refers to a group of heritable defects of hemoglobin synthesis ...

Analysts at Precedence Research expect the gene-editing market to grow 15.7% annually and reach $29.9 billion by 2032, ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $508.38, a high estimate of ...

CRISPR Therapeutics' first therapy is called Casgevy. It treats sickle cell disease (SCD) and beta thalassemia, both rare ...

CRISPR Therapeutics' stock may seem boring due to slow FDA trial and rollout process, but it's a strong long-term investment.

There are two main types of thalassemia: alpha and beta thalassemia, each with various subtypes. The severity of symptoms ...

He also believes there’s still too few of the therapies on the market to draw any sweeping conclusions on reasons for their ...

BMO Capital Markets managing director of biopharma equity research Evan Seigerman joins Market Domination to discuss the best ...

Beta-thalassemia is a rare blood disorder caused by a genetic defect in hemoglobin. Several manufacturers are developing novel treatments for the disease, including Vertex, which has partnered ...

Developed in collaboration with Vertex Pharmaceuticals, this therapy treats sickle cell disease and transfusion-dependent ...